Chronic Kidney DiseasesNCT05696028
Comparison of Different Gfr Measurements in Chronic Kidney Diseases
An observational study of Chronic Kidney Diseases, run by Assiut University.
Trial summary
Comparison of different Gfr measurements in Chronic Kidney Diseases Read more about this study
- Who is it for?
- Ages 40 to 60 years
- Conditions the study is for
- Chronic Kidney Diseases
- What is being tested?
- Gamma counter
- Type of treatment
- Medical device
- How many people
- 166 participants
- Where
- No sites listed yet
- Study dates
- 1 Feb 2023to 1 Dec 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 60 years
- All sexes
- Adult
Study population: Patients proven or suspected CKD
Who may be able to join
- patients with proven or suspected CKD who will be referred to nuclear medicine departement of Assuit University hospital and will undergo dynamic renal imaging.
Who cannot join
- Severely ill patients
- Disturbed conscious level
- Patients on dialysis
- patients have oedema or ascites
Trial locations and contacts
No sites are listed yet.
About this study
Official title: Resident Doctor at Clinical Pathology Departement
Comparison of different Gfr measurements in Chronic Kidney Diseases
Read the detailed description
Comparison of gfr measured by different method as radionuclide method and creatinine clearance
- Conditions
- Chronic Kidney Diseases
- Being tested
- Gamma counter
- Medical subject headings
- Renal Insufficiency, Chronic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Gamma counterDevice
Also called Radionucide method
DTpA
What is being measured
The primary outcome is the main question the study is designed to answer.
Is to Compare gfr measured by radionuclide method to gfr measured by creatinine clearance in patients with CKD
Gfr can be measured by quantification of plasma and standard volume sample using a quality controlled gamma_counter and Gamma camera these techniques the central assumption that the tracer is cleared solely by glomerular filtration.
Measured: 1year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jan 2023
- Study start1 Feb 2023 (estimated)
- Primary completion1 Sep 2023 (estimated)
- Study completion1 Dec 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Kidney DiseasesStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 166 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Asmaa zidan, Assiut University
- Investigators
- Asmaa Zidan, doctor, Principal investigator, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05696028
- Sponsor's protocol ID
- Clinical pathology
- Status last verified
- Jan 2023
- First submitted
- 28 Dec 2022
- Last updated
- 25 Jan 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Jan 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Resident Doctor at Clinical Pathology Departement
- ClinicalTrials.gov ID
- NCT05696028
- Acronym / sponsor ID
- Clinical pathology
- Conditions
- Chronic Kidney Diseases
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 166 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 1 Feb 2023 (estimated)
- Primary completion
- 1 Sep 2023 (estimated)
- Study completion
- 1 Dec 2023 (estimated)
- First posted
- 25 Jan 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Comparison of different Gfr measurements in Chronic Kidney Diseases
Detailed description
Comparison of gfr measured by different method as radionuclide method and creatinine clearance
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 40 to 60 years
- Sex
- All
- Age groups
- Adult
- Study population
- Patients proven or suspected CKD
Key inclusion criteria (1 listed)
- patients with proven or suspected CKD who will be referred to nuclear medicine departement of Assuit University hospital and will undergo dynamic renal imaging.
Key exclusion criteria (4 listed)
- Severely ill patients
- Disturbed conscious level
- Patients on dialysis
- patients have oedema or ascites
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Gamma counterAlso: Radionucide methodDTpA | Device | – |
Primary outcome
Is to Compare gfr measured by radionuclide method to gfr measured by creatinine clearance in patients with CKD
Time frame: 1year
Gfr can be measured by quantification of plasma and standard volume sample using a quality controlled gamma_counter and Gamma camera these techniques the central assumption that the tracer is cleared solely by glomerular filtration.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Jan 2023.
Related trials for Chronic Kidney Diseases
Active, not recruitingPhase 2
Safety and Efficacy of Empagliflozin in Hemodialysis
End Stage Renal Disease
RecruitingPhase 3
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
Berger Disease, Bergers Disease
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruiting
Hypothermic Kidney Machine Perfusion With Omnisol
End Stage Renal Disease (ESRD), Kidney Transplant
Not yet recruiting
An Individuation Intervention to Reduce Socioeconomic Disparities in Chronic Kidney Disease Care
Chronic Kidney Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Asmaa Zidan, doctor principal investigator
Assiut University
Questions about this trial
What is this clinical trial studying?
An observational study of Chronic Kidney Diseases, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 25 Jan 2023. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Asmaa Zidan, doctor (01094828826, Zasmaa650@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Is to Compare gfr measured by radionuclide method to gfr measured by creatinine clearance in patients with CKD (time frame: 1year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jan 2023.